OTHER BLOGS

Legend Biotech Reports Second Quarter 2023 Results and Recent Highlights

Legend Biotech Reports Second Quarter 2023 Results and Recent Highlights

Aug 15, 2023

Legend Biotech to Host Investor Conference Call on Second-Quarter Results

Legend Biotech to Host Investor Conference Call on Second-Quarter Results

Aug 03, 2023

Legend Biotech Announces Submission of Supplemental Application to the U.S. FDA for Expanded Use of CARVYKTI® (ciltacabtagene autoleucel)

Legend Biotech Announces Submission of Supplemental Application to the U.S...

Jun 06, 2023

Ciltacabtagene Autoleucel (cilta-cel) Reduced Risk of Disease Progression or Death by 74% vs Standard Regimens for Adult Patients with Relapsed and Refractory Multiple Myeloma in CARTITUDE-4 Study

Ciltacabtagene Autoleucel (cilta-cel) Reduced Risk of Disease Progression o..

Jun 05, 2023

Legend Biotech Announces Submission to the European Medicines Agency for Expanded Use of CARVYKTI® (ciltacabtagene autoleucel)

Legend Biotech Announces Submission to the European Medicines Agency for Ex..

May 25, 2023

close

You are about to leave LegendBiotech.com

We use cookies to improve your experience on our website, measure performance, understand our audience, for advertising and support purposes. You can always change your preferences or opt out from our use of cookies.